| |
 |
Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| RE40792 |
Health supplements containing phyto-oestrogens, analogues or metabolites thereof
|
|
| Patent Drawings: | |
| Inventor: |
Kelly |
| Date Issued: |
June 23, 2009 |
| Application: |
09/602,191 |
| Filed: |
May 19, 1993 |
| Inventors: |
Kelly; Graham Edmund (Northbridge, AU)
|
| Assignee: |
Novogen Research Pty Ltd (New South Wales, AU) |
| Primary Examiner: |
Lewis; Patrick T |
| Assistant Examiner: |
|
| Attorney Or Agent: |
Finnegan, Henderson, Farabow, Garrett & Dunner L.L.P. |
| U.S. Class: |
514/182; 424/423; 424/449; 424/451; 424/464; 426/545; 514/25; 549/403; 549/406 |
| Field Of Search: |
424/195.1; 424/464; 424/423; 424/449; 424/451; 514/182; 514/25; 426/545; 549/403; 549/406 |
| International Class: |
A61K 31/56 |
| U.S Patent Documents: |
|
| Foreign Patent Documents: |
B-80655/87; A-10227/95; A-24813/97; A-73072/98; A-27714/00; 44 32 947; 0129667; 0135172; 0136569; 0 412 211; 0426998; 0 671 170; 0 682 877; 0 682 887; 0 795 553; 0 906 761; 1 322 844; 1 482 238; 1 495 189; 1482238; S50-0035393; S50-101360; S50-160483; S61-247396; 61-246124; 61246124; 62-106016; S62-106017; 62126186; H01-042427; H01-226824; 01258669; 1-258669; 267218; 02-067218; 02069165; H02-124883; 2160722; 02-160722; 03047049; 04-283518; 05-170756; H05-170756; H06-040876; H06-040909; H06-086682; H06-321752; H07-173148; H09-067362; H10-059956; WO 91/14429; WO93/23069; WO94/23716; WO 95/03293; WO 96/10341; WO 96/10341; WO 97/06273; WO 97/46208; WO 98/08503; WO 98/48790; WO 98/49153; WO 98/52546; WO 98/56373; WO 99/11260; WO 99/11263; WO 99/18927; WO 99/36050; WO 99/37633; WO 99/43335; WO 00/03707; WO 00/16759; WO 00/49009; WO 00/54753; WO 00/62765; WO 00/64438; WO 00/66576; WO 03/035635; WO 03/086386 |
| Other References: |
Sharma, Atherosclerosis, (1979), vol. 33, pp. 371-375. cited by examiner.
U.S. Appl. No. 09/546,565 filed Apr. 11, 2000, Kelly et al. cited by other.
U.S. Appl. No. 10/176,762 filled Jun. 21,2002, Kelly et al. cited by other.
U.S. Appl. No. 10/177,387 filed Jun. 21, 2002, Kelly et al. cited by other.
U.S. Appl. No. 10/181,549 filed Jan. 22, 2001, Husband et al. cited by other.
U.S. Appl. No. 10/212,847 filed Aug. 5, 2002, Kelly et al. cited by other.
U.S. Appl. No. 10/250,858 filed Jan. 16, 2002, Husband. cited by other.
U.S. Appl. No. 10/421,659 filed Apr. 22, 2003, Kelly. cited by other.
U.S. Appl. No. 10/469,957 filed Mar. 8, 2002, Heaton et al. cited by other.
U.S. Appl. No. 10/471,668 filed Mar. 15, 2002, Husband et al. cited by other.
U.S. Appl. No. 10/493,390 filed Oct. 25, 2002, Kelly et al. cited by other.
U.S. Appl. No. 10/510,837 filed Oct. 8, 2004, Kelly et al. cited by other.
U.S. Appl. No. 10/611,151 filed Jul. 2, 2003, Kelly. cited by other.
U.S. Appl. No. 10/636,902 filed Aug. 6, 2003, Kelly et al. cited by other.
U.S. Appl. No. 10/704,385 filed Nov. 7, 2003, Heaton et al. cited by other.
U.S. Appl. No. 10/799,022 filed Mar. 11, 2004, Kelly. cited by other.
U.S. Appl. No. 10/851,270 filed Mar. 20, 2004, Heaton et al. cited by other.
U.S. Appl. No. 10/947,356 filed Sep. 21, 2004, Kelly et al. cited by other.
U.S. Appl. No. 11/024,512 filed Dec. 28, 2004, Kelly et al. cited by other.
Partial European Search Report for EP 04103669, dated Dec. 22, 2004. cited by other.
Office Action issued in U.S. Patent No. 6,146,668 on Sep. 9, 1998. cited by other.
Amendment and Response filed in U.S. Pat No. 6,146,668 on Mar. 8, 1999. cited by other.
Office Action issued in U.S. Patent No. 6,146,668 on Jun. 7, 1999. cited by other.
Amendment After Final filed in U.S .Patent No. 6,146,668 on Dec. 7, 1999. cited by other.
Notice of Allowance with Examiner's Amendment issued in U.S. Patent No. 6,146,668 on Jan. 11, 2000. cited by other.
Preliminary Amendment filed in U.S. Appl. No. 09/546,565 on Apr. 11, 2000. cited by other.
Office Action issued in U.S. Appl. No. 09/546,565 on Oct. 2, 2002. cited by other.
Amendment filed in U.S. Appl. No. 09/546,565 on Apr. 2, 2003. cited by other.
Office Action issued in U.S Appl. No. 09/546,565 on Jun. 20, 2003. cited by other.
Amendment filed in U.S. Appl. No. 09/546,565 on Nov. 20, 2003. cited by other.
Office Action issued in U.S. Appl. No. 09/546,565 on Feb. 25, 2004. cited by other.
Amendment filed in U.S. Appl. No. 09/546,565 on Aug. 25, 2004. cited by other.
Notice of Allowance with Examiner's Amendment issued in U.S. Appl. No. 09/546,565 on Nov. 16, 2004. cited by other.
Amendment filed in U.S. Appl. No. 09/546,565 on Jan. 26, 2005. cited by other.
Office Action issued in U.S. Pat. No. 6,340,703 on Jul. 9, 1999. cited by other.
Office Action issued in U.S. Pat. No. 6,340,703 on Apr. 27, 2000. cited by other.
Amendment and Responses filed in U.S. Pat. No. 6,340,703 on Oct. 27, 2000. cited by other.
Office Action in U.S. Pat. No. 6,340,703 on Feb. 9, 2001. cited by other.
Amendment filed in U.S. Pat. No. 6,340,703 on May 31, 2001. cited by other.
Office Action issued in U.S. Appl. No. 09/986,509 on Jul. 23, 2002. cited by other.
Amendment filed in U.S. Appl. No. 09/986,509 on Dec. 23, 2002. cited by other.
Restriction Requiremnet issued in U.S. Appl. No. 09/986,509 on Apr. 18, 2003. cited by other.
Response in Restriction Requirement filed in U.S. Appl. No. 09/986,509 on Oct. 8, 2003. cited by other.
Office Action issued in U.S. Appl. No. 09/986,509 on Feb. 6, 2004. cited by other.
Amendment and Responses filed in U.S. Appl. No. 09/986,509 on Aug. 5, 2004. cited by other.
Office Action issued inU.S. Appl. No. 09/647,092 on Oct. 23, 2001. cited by other.
Amendment filed in U.S. Appl. No. 09/647,092 on Mar. 25, 2002. cited by other.
Office Action issued in U.S. Appl. No. 09/647,092 on Jun. 18, 2002. cited by other.
Amendment After Final filed in U.S. Appl. No. 09/647,092 on Dec. 17, 2002. cited by other.
Restriction Requirement issued in U.S. Appl. No. 09/647,092 on Feb. 10, 2003. cited by other.
Amendment and Response to Restriction Requirement filed in U.S. Appl. No. 09/647,092 on Mar. 11, 2003. cited by other.
Notice of Allowance with Statement of Reasons issued in U.S. Appl. No. 09/647,092 on Apr. 8, 2003. cited by other.
Preliminary Amendment filed in U.S. Appl. No. 10/459,537 on Jun. 12, 2003. cited by other.
Office Action issued in U.S. Appl. No. 09/914,035 on Dec. 18, 2002. cited by other.
Preliminary Amendment filed in U.S. Appl. No. 10/600,004 on Jun. 18, 2003. cited by other.
Office Action issued in U.S. Appl. No. 10/600,004 on Jun. 17, 2004. cited by other.
Amendment filed in U.S. Appl. No. 10/600,004 on Dec. 13, 2004. cited by other.
Statutory Declaration of Fiona Bathgate, declared Mar. 24, 1998, 4 pages. cited by other.
Statutory Declaration of Fiona Bathgate (Amended), declared Oct. 26, 1998, 2 pages. cited by other.
Statutory Declaration of Nancy Beckham, declared Sep. 8, 1998, 20 pages. cited by other.
Statutory Declaration of Kerry Martin Bone, declared Oct. 5, 1998, 31 pages. cited by other.
Statutory Declaration of Jennifer Carpinelli, declared Oct. 21, 1998, 2 pages. cited by other.
Statuory Declaration of G. Clements, declared Jan. 27, 1999, 2 pages. cited by other.
Statuory Declaration of Julie Hill, declared Apr. 4, 1998, 2 pages. cited by other.
Statutory Declaration of Norbert Krause, declared Nov. 5, 1998, 23 pages. cited by other.
Statuory Declaration of Ngaire Petit-Young, declared Nov. 5, 1998, 3 pages. cited by other.
Statutory Declaration of Hubert Regtop, declared Nov. 24, 1998, 53 pages. cited by other.
Statutory Declaration of Joseph Nicolas Van Haaster, declared Jan. 26, 1999, including Exhibit "JNVH-1", 20 pages. cited by other.
Constantinou, A. et al., "Induction of Differentiation and DNA Strand Breakage in Human HL-60 and K-562 Leukemia Cells by Genistein," Cancer Res.50:2618-2624 (1990). cited by other.
Kiguchi, K. et al., "Genistein-Induced Cell Differentittion and Protein-Linked DNA Strand Breakage in Human Melanoma Cells," Cancer Comm.2(8):271-278 (1990). cited by other.
Liu, Y. et al., "Effects of solid dispersion of daidzein on the blood pressure of spontaneously hypertensive rates," Chemical Abstracts, 115(8):406, Abstract No. 78763p (1991). cited by other.
Naim, M. et al., "Antioxidative and Antihemolytic Activities of Soybean Isoflavones," J. Agric. Food Chem. 24(6):1174-1177 (1976). cited by other.
Oenobiol Feminite Dietary Supplement, International Product Alert 16(12) (1999), and Oenobiol Product Insert ( 3 pages). cited by other.
Okura, A. et al., "Effect of Genistein on Topoisomerase Activity and on the Growth of [Val 12]Ha-ras-transformed NIH 3T3 Cells," Biochem. Biophys. Res. Comm. 157(1):183-189 (1988). cited by other.
Tamura, S. et al., "Chemical Studies on `Clover Sickness.` Part I. Isolution and Structural Elucidation of Two New Isoflavonoids in Red Clover," Agr. Biol. Chem. 33(3):391-397 (1969). cited by other.
Van De Weijer, P. et al., "Isoflavones from red clover (Promensil.RTM.) significantly reduce menopausal hot flush symptoms compared with placebo," Maturitas 42:187-193 (2002). cited by other.
Yamashita, Y. et al., "Induction of mammalial topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, Genistein and Orobol," Biochem. Pharmacol. 39(4):737-744 (1990). cited by other.
Statutory Declaration of Graham Edmund Kelly with two Exhibits (GK1 and GK2), dated Oct. 22, 2003. cited by other.
Supplementary European Search Report for EP 93 90 9679, dated Apr. 25, 1997, 3 pages. cited by other.
Response filed in U.S. Appl. No. 10/611,087 on Oct. 12, 2005. cited by other.
Office Action mailed in U.S. Appl. No. 10/611,087 on Mar. 27, 2006. cited by other.
Response filed in U.S. Appl. No. 10/611,087 on Jun. 26, 2006. cited by other.
Office Action mailed in U.S. Appl. No. 10/611,087 on Nov. 14, 2006. cited by other.
Preliminary Amendment filed in U.S. Appl. No. 11/490,865 on Jul. 20, 2006. cited by other.
U.S. Appl. No. 09/421,069 filed Oct. 19, 1999, Kelley. cited by other.
U.S. Appl. No. 09/986,509 filed Nov. 9, 2001, Kelly. cited by other.
U.S. Appl. No. 10/274,371 filed Oct. 21, 2002, Kelly. cited by other.
U.S. Appl. No. 10/459,537 filed Jun. 12, 2003, Kelly et al. cited by other.
U.S. Appl. 10/600,004 filed Jun. 18, 2003, Kelly et al. cited by other.
U.S. Appl. No. 10/611,087 filed Jul. 2, 2003, Kelly. cited by other.
U.S. Appl. No. 10/611,151 filed Jul. 2, 2003, Kelly. cited by other.
Bezuidenhoudt et al., "Synthesis of Isoflavanoid Oligomers Using a Pterocarpan as Inceptive Electrophile," J. Chem. Soc. Perkin Transactions I, pp. 2767-2778 (1984). cited by other.
Bingham et al., "Phyto-oestrogens: where are we now?," British Journal of Nutrition, vol. 79, pp. 393-406 (1998). cited by other.
Peterson et al. "Genistein Inhibition of the Growth of Human Breast Cancer Cells: Independence from Estrogen Receptors and the Multi-Drug Resistance Gene," Biochemical ad Biophysical Research Communications, vol. 179, No. 1, pp. 661-667 (Aug. 30,1991). cited by other.
Wei et al. "Antioxidant and Antipromitional Effects of the Soybean Isoflavone Genistein," Proceedings of the Society for Experimental Biology and Medicine, vol. 208, No. 1, pp. 124-130 (Oct. 1993). cited by other.
Adlercreutz, H. et al., "Effect of Dietary Components, Including Lignans and Phytoestrogens, on Enterohepatic Circulation and Liver Metabolism of Estrogens and on Sex Hormones Binding Globulin (SHBG)," J. steroid Biochem, vol. 27, No. 4-6, pp.1135-1144 (1987). cited by other.
Akkad, Andrea A. et al., "Abnormal Uterine Bleeding on Hormone Replacement: The Importance of Intrauterine Structural Abnormalities," Obstetrics & Gynecology, vol. 86, pp. 330-334 (1995). cited by other.
Alegrio, L.V. et al.; "Diarylheptanoids and Isoflavonoids from Centrolobium Species"; Phytochemistry, vol. 28, No. 9, pp. 2359-2362, (1989). cited by other.
Al-Maharik, N.I. et al., "Synthesis of C-C-Bridged Bis-Isoflavones," J. Org. Chem., vol. 65, pp. 2305-2308, (2000). cited by other.
Anderson et al. "Biphasic Effects of Genistein on Bone Tissue in the Ovariectomized, Lactating Rat Model," P.S. E. B. M. vol. 217, pp. 345-350 (1998). cited by other.
Baber, R. et al. "The effect of an isoflavone dietary supplement (Rismostil) on serum lipids, forearm bone density and endometrial thickness in post-menopausal women," Proc 10.sup.th Annual Meeting of the North American Menopause Society, New York,Sep. 23-25, 1999. cited by other.
Bannerjee et al., "Polarography of Flavanone and Isoflavone", J. Electrochem. Soc. India, vol. 47, No. 4, pp. 237-244, (Oct. 1998). cited by other.
Bannwart, C. et al., "Identification of the isoflavonic phytoestrogen daidzein in human urine," Clinica Chimica Acta, vol. 136, Nos. 2-3, pp. 165-172, (Jan. 1984). cited by other.
Beylot "Clinical signs of skin ageing." Revue Francaise de Gynecologie et d'Obstetrique, (1991) 86/6 (433-441) ISSN: 0035-290X. cited by other.
Burali, C. et al., "Synthesis and Anti-Rhinovirus Activity of Halogen-Substituted Isoflavenes and Isoflavans," European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, 22(2):119-123 (Apr. 1987). cited by other.
Cassady, J.M. et al., Use of a Mammalian Cell Culture Benzo(a)pyrene Metabolism Assay for the Detection of Potential Anticarcinogens from Natural Products: Inhibition of Metabolism by Biochanin A, an Isoflavone from Trifolium pratense L, CancerResearch, vol. 48 (22), pp. 6257-6261, (Nov. 1998). cited by other.
Caswell, A. (ed) "Hypolipidaemic Agent," MIMS Annual 23.sup.rd edition, pp. 2-152 to 2-169, Singapore (1999). cited by other.
Chan K. et al., "Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women," Lancet; 355(9222):2185-8, Jun. 24, 2000. cited by other.
Chang et al., "Metabolities of daidzein and genistein and their biological activities." Journal of Natural Products (1995), 58(12), pp. 1901-1905, ISSN:0163-3864. cited by other.
Chang Y., "Microwave-Mediated Synthesis of Anticarcinogenic Isoflavones from Soybeans," J Argric Food Chem. 1994, 42: 1869-1871. cited by other.
Chicago Center for Clinical Research, Company Press Release Mar. 13, 2000, "Chicago Center for Clinical Research Study suggests New, More Effective Way to Treat Older Women with High Cholesterol". cited by other.
Clifton-Bligh, P. et al., "The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism," Menopause (in submission), pp. 1-27, 2000. cited by other.
Collins, B.M. et al., "The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast," Steroids, vol. 62, pp. 365-372, (Apr. 1997). cited by other.
Deschamps-Vallet, C. et al., "Transformation Du Cation Isoflavyium en Phenyl-3 Coumarines, Isoflavenes-3 et Isoflavannes," Tetrahedron Letters, 24(37):3993-3996 (1983). cited by other.
Doren, M. et al., "Identification and Treatment of Postmenopausal Women at Risk for the Development of Osteoporosis," International Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 20, No. 11, pp. 431-433 (1992). cited by other.
Dubey et al. "Phytoestrogens Inhibit Growth and MAP Kinase Activity in Human Aortic Smooth Muscle Cells," Hypertension, vol. 33 (part II), pp. 177-182, (1999). cited by other.
Ellis, G.P. (ed.); "Chromenes, Chromanones, and Chromones"; pp. 256-260; publidhed by John Wiley & Sons, 1977. cited by other.
Evans, D. et al., "Ovarian Cancer Family and Prophylactic Choices," Journal of Medical Genetics, pp. 416-418, 1991. cited by other.
Evans, M. et al., "Hormones Replacement Therapy: Management of Common Problems," Mayo Clin. Proc, vol. 70, pp. 800-805, (1995). cited by other.
Fanti et al. "The Phytoestrogen Genistein Reduces Bone Loss in Short-Term Ovariectomized Rats," Osteoporosis Int., vol. 8, pp. 274-281, (1998). cited by other.
Goh, J.T.W. et al., "Postmenopausal Endometrioma and Hormonal Replacement Therapy," Aust NZ J. Obstet Gynaecol, vol. 32, pp. 384-385 (1992). cited by other.
Graham, T. L., "Flavonoid and Isoflavonoid Distribution in Developing Soybean Seedling Tissues and in Seed and Root Exudates," Pharm. Physiol. vol. 95, pp. 594-603, (1991). cited by other.
Grodstein, F., et al., "Postmenopausal Hormone Use and Cholecystectomy in a Large Prospective Study," Obstetrics & Gynecology, vol. 83, No. 1, pp. 5-11 (1994). cited by other.
Hebert, P. et al., (1997), "Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials," JAMA 278(4):313-21. cited by other.
Hodgson, J. et al., (1998), "Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomised controlled trial in humans," Journal of Nutrition, 128: 728-332. cited by other.
Hulley, S. et al., (1998), "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women," JAMA 280(7): 605-613. cited by other.
Inoue, N., 1964, "Studies of Synthetic Isoflavones, V. The Reduction of Isoflavone," originally from Bull. Chem. Soc. Japan, May 1964, 37(5): 601-605, cited in ISTN International, CAPLUS database, (Columbus, Ohio), No. 61: 32297 (2 pages). cited byother.
Jurd, L. et al.; "Phenolic and Quinoidal Constituents of Dalbergia Retusa," Tetrahedron Letters, vol. 21, pp. 2149-2152, (1972). cited by other.
Kao, Y., et al., "Molecular Basis of the Inhibition of Human Aromatase (Estrogen Syntethase) by Flavone and Isoflavone Phytoestrogens: A Site-directed Mutagensis Study," Environmental Health Perspectives, vol. 106, No. 2, pp. 85-92 (1998). cited byother.
Kelly et al., "Metabolities of dietary (soya) isoflavones in human urine," Clinica Chimica Acta 223(1-2), pp. 9-22 (Dec. 31, 1993). cited by other.
Kelly , S. A. et al., "Protein Tyrosine Phosphorylation Mediates TNF-Induced Endothelial-Neutrophil Adhesion in Vitro", The American Physiological Society, 274 (2Pt2), pp. H513-H519, (1998). cited by other.
Lamberton, et al., "Catalytic Hydrogenation of Isoflavones. the Preparatoin of (.+-.)-Equol and Related Isoflavans", Aust. J. Chem. vol. 31, pp. 455-457, (Feb. 1978). cited by other.
Liepa, A.J. "A Synthesis of Hydroxylated Isoflavylium Salts and Their Reduction Products", Aust. J. Chem., vol. 34, pp. 2647-2655, (1981). cited by other.
Lindner, H.R., "V/1 Occurrence of Anabolic Agents in Plants and their Importance," Environmental Quality and Safety Supplement, Thieme, Stuttgart, Germany, 1976, 5: 151-158. cited by other.
Liu, Y. et al., "Abstract No. 78763p; Effects of solid dispersion of diadzein on the blood pressure of spontaneously hypersensitive rats," Chemical Abstracts, vol. 115, No. 8, p. 466 (Aug. 26, 1991). cited by other.
Makela, S. et al. "Inhibition of 17.beta.-Hydroxysteroid Oxidoreductase by Flavonoids in Breast and Prostate Cancer Cells," pp. 310-316 (1998). cited by other.
May, M. J. et al., "Effects of Protein Tyrosine Kinase Inhibitors on Cytokine-Induced Adhesion Molecule Expression by Human Umbilical Vein Endothelial Cells", British Journal of Pharmacology, No. 118, pp. 1761-1771, (1996). cited by other.
Mazur et al.; "Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment*--Naturally occurring oestrogens in food," Pure & Appl. Chem. 70(9), pp. 1759-1776 (1998). cited by other.
Namnoum, A.B., et al., "Incidence of symptom recurrence after hysterectomy for endometriosis," Fertility and Sterility, vol. 64, No. 5, pp. 898-902 (1995). cited by other.
Nestel, P. et al., (1997), "Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and peri-menopausal women," Arteriosclerosis, Thrombosis and Vascular Biology 17: 3392-3398. cited by other.
Nestel, P. et al., (1999), "Isoflavones from red clover improves systemic arterial compliance but not plasma lipids in menopausal women," Journal of Clinical Endocrinology and Metabolism 84: 895-898. cited by other.
Palmetshofer, A. et al., ".alpha.-Galactosyl Epitope-Mediated Activation of Porcine Aortic Endothelial Cells", Transplantation, vol. 65, No. 7, pp. 971-978, (Apr. 15, 1998). cited by other.
Panchagnula, R. et al., "Transdermal iontophoresis revisited," Curr. Opin. Chem. Biol, Aug. 2000; 4(4):468-73. cited by other.
Parfitt, K., Martindale 32.sup.nd edition, "The complete drug reference," (1999), 32.sup.nd Edition,. Pharmaceutical Press, London, pp. v. and vi. cited by other.
Peterson, G. et al., "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," The Prostate, vol. 22, No. 4, pp. 335-345, (1993). cited by other.
Peterson, G. et al., "Genistein Inhibition of the Growth of Human Breast Cancer Cells: Independence From Estrogen Receptors and the Multi-drug Resistance Gene," Biochemical and Biophysical Research Communications, vol. 179, No. 1, pp. 661-667, (Aug.1991). cited by other.
Potter, S. et al., (1998), "Soy protein and isoflavones: their effect on blood lipids and bone density in postmenopausal women," American Journal of Clinical Nutrition, 68(Suppl):1375S-1379S. cited by other.
Sacks, F. et al., (1996), "The effect of pravastain on coronary events after myocardial infarction in patients with average cholestrol levels," Cholesterol and Recurrent Events Trial Investigators, New England Journal of Medicine, 335(14):1001-9.cited by other.
Samman, S. et al., (1999), "The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in pre-menopausal women," Atherosclerosis 147:277-283. cited by other.
Sanchez-Guerrero, J. et al., "Postmenopausal Estrogen Therapy and the Risk for Developing Systemic Lupus Erythematosus," Annals of Internal Medicine, vol. 122, No. 6, pp. 430-433 (1995). cited by other.
Sbarouni, E. et al., (1998), "The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease," Journal of the American College ofCardiology 32(5): 122-50. cited by other.
Scandiavian Simvastation Survival Study Group, (1994), "Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavn Simvastatin Survivl Study (4S)," Lancet 344:1383-89. cited by other.
Schultz, "Isoflavonglucoside Formononetin-7-glucosid und Biochanin A-7-glucosid in Trifolium pratense L.," Die Naturwissenschaften, 52(18), p. 517, Sep. 1965. cited by other.
Sener, A.B., et al., "The effects of hormone replacement therapy on uterine fibroids in postmenopausal women," Fertility and Sterility, vol. 65, No. 2, pp. 354-357 (1996). cited by other.
Siddiqui et al. "Hypolipidemic principles of Cicer Arietinum: Biochanin-A and Formononetin," Lipids, vol. 11, No. 3, pp. 243-246, (1975). cited by other.
Stampfer, M. et al., "A Prospective Study of Cholesterol, Apolipoproteins, and the Risk of Myocardial Infarction," The New England Journal of Medicine, vol. 325, No. 6, pp. 373-381, (1991). cited by other.
Szabo et al., 1973, "The Selective Reduction of Isoflavon," Tetrahedron Letters, 19: 1659-1662. cited by other.
Troisi, R.J., et al., "Menopause, Postmenopausal Estrogen Preparations and the Risk of Adult-Onset Asthma," Am J Respir Crit Care Med, vol. 152, pp. 1183-1188 (1995). cited by other.
WahaIa, K. et al., "Hydrogen Transfer Reduction of Isoflavones," Heterocycles, 28(1):183-186 (1989). cited by other.
Wang, C., et al., "Phytoestrogen Concentration Determines Effects on DNA Synthesis in Human Breast Cancer Cells," Nutrition and Cancer, 28(3), pp. 236-247 (1997). cited by other.
Weber, C., "Involvement of Tyrosine Phosphorylation in Endothelial Adhesion Molecule Induction", Immunologic Research, No. 15, pp. 30-37, (1996). cited by other.
Welshons, W.V. et al., "Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactn and the phytoestrogen equol," Breast Cancer Research and Treatment, vol. 10, 169-175, (1987). cited by other.
Whalley, W.B.; "5.4'-Dihydroxy-8-Methylisoflavone, and a Note on Lotoflavin," Journal of the Chemical Society, pp. 1833-1837, (1957). cited by other.
Winship, K.A., "Unopposed estrogens," Adv. Drug React. Ac. Pois. Rev., vol. 1, pp. 37-66, (1987). cited by other.
Yahara, S. et al., "Isoflavan and Related Compounds from Dalbergia odorifera. I " Chem, Pharm. Bull. 37(4): 979-987 (Apr. 1989). cited by other.
Grunert E. and Woelke, G., "Isoflavone in einigen Wei.beta.-und Rothkleesorten und ihre oestrogene Wirksamkeit bei juvenilen Mausen", Deutsche Tierarztliche Wochenschrift, 74 Jahrgang 1967, p. 431-433. cited by other.
Naim, Michael, Treatise, The Isolation, Characterization and Biological Activity of Isoflavones from Soybeans, Submitted to the Senate of the Hebrew University of Jerusalem--Oct. 1974. cited by other.
PAJ Abstract corresponding to JP 1042427 A (Feb. 14, 1989). cited by other.
Sharma, R.D., "Effect of various isoflavones on lipid levels in triton-treated rats", Atherosclerosis, 33:271-375 (1979). cited by other.
Weinberg, David S. et al., "Identification and Quantification of Anticarcinogens in Garlic Extract and Licorice Root Extract Powder", Journal of High Resolution Chromatography, 15:641-654 (1992). cited by other.
EPO Examination Report dated Mar. 8, 2002. cited by other.
The Merck Index, 8.sup.th Ed., "Geinstein", and "Formonetin," pp. 320, 484, and 469-470 [respectively], (1968). cited by other.
Walz, E., "Isoflavon-un Saponin-Glucoside in Soja Hispida," Justus Liebigs Am. Chem., vol. 489, pp. 118-155 (1931). cited by other.
Adlercreutz, H. et al., "Determination of Urinary Lignans and Phytoestrogen Metabolites, Potential Antiestrogens and Anticarcinogens, in Urine of Women on Various Habitual Diets," J. Steroid Biochem, vol. 25, No. 58, pp. 791-797 (1986). cited byother.
Adlercreutz, Herman et al., "Dietary phyto-oestrogens and the menopause in Japan," The Lancet, pp. 1295-1299 (1982). cited by other.
Adlercreutz, Herman et al., "Dietary Phytoestrogens and Cancer In Vitro and In Vivo Studies," J. Steroid Biochem Molec. Biol., vol. 41, No. 3-8 pp. 331-337 (1992). cited by other.
Adlercreutz, H. et al., "Excretion of the Lignans Exterolactone and Enterodiol and of Equol in Omnivorous and Vegetarian Postmenopausal Women and in Women with Breast Cancer," The Lancet, pp. 1295-1299 (1982). cited by other.
Adlercreutz, H., "Lignans and Phytoesrogens", Front gastrointest. Res., vol. 14, pp. 165-176 (1988). cited by other.
Adelcreutz, Herman et al., "Urinary Excretion of Lignans and Isoflavonoids Phytoestrogens in Japanese Men and Women Consuming a Traditional Japanese Diet," Am. J. Clin. Nutr., vol. 54, pp. 1093-1100 (1991). cited by other.
Adlercreutz, Herman, "Western Diet and Western Diseases: Some Hormonal and Biochemical Mechanisms and Associations", Scand. J. Clin. Lab. Invest, Suppl. vol. 201 pp. 3-23 (1990). cited by other.
Anderson M.D., James et al., "Meta-Analysis of the Effects of Soy Protein Intake on Serum Lipids," New Eng. J. Med., vol. 333, No. 5, pp. 276-282 (1995). cited by other.
Barnes, Stephen et al., "Soybeans Inhibit Mammary Tumors in Models of Breast Cancer," Mutagens and Carcinogens in the Diet, pp. 239-253 (1990). cited by other.
Bailey, E.T. et al., "Isoflavone Concentrations in the Leaves of the Species of the Genus Trifolium, Section Calycomporhum," Aust. J. Agric. Res., vol. 22, No. 5, pp. 731-736 (1971). cited by other.
Barrow, N.J., "Nutrient Potential and Capacity," Aust. J. Agric. Res., vol. 17, pp. 849-861 (1966). cited by other.
Barrow, N.J. et al., "Nutrient Potential and Capacity", Aust. J. Agric. Res., 18:55-62 (1966). cited by other.
Beck, A.B., "The Oestrogenic Isoflavones of Subterranean Clover," Aust. J. Agric. Res., 15:223-230 (1964). cited by other.
Beckham, N., "Menopause," The Family Guide to Natural Therapies, Greenhouse Publications, pp. 41-42, 50 (1988). cited by other.
Beckham, Nancy, "Herbal Help to Avoid Menopause Symptoms," Australian Wellbeing, No. 29, pp. 74-76 (1988). cited by other.
Beckham, Nancy, "Phyto-Oestrogens and Compounds that Affect Oestrogen Metabolism--Part I," Aust. J. Med. Herbalism, vol. 7, No. 1, pp. 11-16 (1995). cited by other.
Beckham, Nancy "Phyto-Oestrogens and Compounds that Affect Oestrogen Metabolism--Part II," Aust. J. Med. Herbalism, vol. 7, pp. 27-33 (1995). cited by other.
Bennetts, H.W. et al., "A Specific Breeding Problem of Sheep on Subterranean Clover Pastures in Western Australia," The Australian Veterinary Journal, vol. 22, pp. 2-12 )1946). cited by other.
Beuker Velasse--Advertising Brochure--with English language translation. cited by other.
Bombardelli, Ezio, "Technologies for the Processing of Medicinal Plants," in Medicinal Plant Industry, Chapt. 7, pp. 85-98 (1991). cited by other.
Bradbury, R.B. et al., "The Chemistry of Subterranean Clover. Part I. Isolation of Formononetin and Genistein," J. Chem. Soc., pp. 3447-3449 (1951). cited by other.
Bradbury R.B. et al., "Estrogens and Related Substances in Plants",in Vitamins and Hormones Advances in Research and Applications, Harris, R.S. et al., eds., pp. 207-233 (1954). cited by other.
Brandi, M.L., "Flavonoids: biochemical effects and therapeutic applications," Bone and Minerals, vol. 19 (Suppl.) S3-S14 (1992). cited by other.
Braden, A. W. H. et al., "Comparison of Plasma Phyto-Oestrogen Levels in Sheep and Cattle After Feeding on Fresh Clover," Aust. J. Agric. Res., vol. 22, pp. 663-670 (1971). cited by other.
Braden, A.W.H. et al., "The Oestrogenic Activity and Metabolism of Certain Isoflavones in Sheep," Aust. J. Agric. Res., vol. 18 pp. 335-348 (1967). cited by other.
British Herbal Compendium, vol. 1, "A handbook of scientific information on widely used plant drugs," BHMA (1992). cited by other.
British Herbal Pharmacopoeia, Published by the British Herbal Medicine Association (1983). cited by other.
Buzzell, R. I., "Inheritance of flavonol glycosides in soybeans," Can. J. Genet. Cytol A(1973), 15(4), 865-7, Abstract Accession No. 1974:143143, reference No. 80:143143. cited by other.
Circle, S. J. et al., "Processing Soy Flours, Protein Concentrates and Protein Isolates," Soybeans: Chemistry and Technology, vol. 1, pp. 294-338 (1972). cited by other.
Coward, Lori et al., "Genistein, Daidzein, and Their .beta.-Glycoside Conjugates: Antitumor Isoflavones in Soybean Foods from American and Asian Diets," J. Agric. Food Chem., vol. 41, pp. 1961-1967 (1993). cited by other.
Culbreth, David M.R., A Manual of Materia Medica and Pharmacology, pp. 19-22. cited by other.
Davies, Lloyd H. et al., "Further Studies on Oestrogenic Activity in Strains of Subterranean Clover (Trifolium Subterraneum L.) In South-Western Australia," Aust. J. Agric. Res. vol. 16, No. 6, pp. 937-950 (1965). cited by other.
Davis, Harold et al., "Extraction," Bentley's Text-Book of Pharmaceuticals, 6th ed., XVIII, pp. 272-273 (1956). cited by other.
Dewick, Paul M., "Isoflavonoids," The Flavonoids, Edited by J.B. Harborne, Published by Chapman and Hall Ltd. (1988). cited by other.
Duker, Eva-Maria et al., "Effects of Extracts from Clinicifuga Racemosa on Gonadotropin Release in Menopausal Women and Ovariectomized Rats," Planta Med., vol. 57, pp. 420-424 (1991). cited by other.
Eldridge, Arthur C., "Determination of Isoflavones in Soybean Flours, Protein Concentrates, and Isolates," J. Agric. Food Chem., vol. 30, pp. 353-355 (1982). cited by other.
Eldridge, A.C., "High-performance liquid chromatography separation of soybean iso-flavones and their glucosides," J. Chrom., vol. 234 pp. 494-496 (1982). cited by other.
Eldridge, Arthur C. et al., "Soybean Isoflavones: Effect of Environment and Variety of Composition," J. Agric. Food Chem., vol. 31 pp. 394-396 (1983). cited by other.
Farmakalidis, Efi et al., "Isolation of 6''O-Acetylgenistin 6''-O-Accetyldaidzin from Toasted Defatted Soyflakes," J. Agric. Food Chem, vol. 33, pp. 385-389 (1985). cited by other.
Farmakalidis et al., "Semi-Preparative High-Performance Liquid Chromatographic Isolation Soybean Isoflavones," J. Chrom., vol. 295, pp. 510-514 (1984). cited by other.
Farnsworth, Norman R. et al., "Potential Value of Plants as Sources of New Antifertility Agents II," J. Pharm. Sciences, vol. 64, No. 5, pp. 717-754 (1975). cited by other.
Francis., C.M. et al., "The Distribution of Oestrogenic Isoflavones in the Genus Trifolium," Aust. J. Agric. Res., 18:47-54 (1967). cited by other.
Francis, C.M. et al., "Varietal Variation in the Isoflavone Content of Subterranean Clover: Its Estimation by a Microtechnique," Aust. J. Agric. Res., 16:557-564 (1965). cited by other.
Gaynor, J.D., "HPLC separation and relative quanitition of kaempferol glycosides in soybean ," Chromatographia (1988), 25(12), 1049-53, Abstract Accession No. 1989:150706, reference No. 110:150706, STN Easy Int'l. cited by other.
Gildersleeve, Rhonda R. et al., "Screening Rose Clover and Subterranean Clover Germplasm for Isoflavones," Crop. Sci., vol. 31 pp. 1374-1376 (1991). cited by other.
Gildersleeve, Rhonda R. et al., "Detection of Isoflavones in Seedling Subterranean Clover," Crop Sci., vol. 31, pp. 889-892 (1991). cited by other.
Gladstones, J.S., "Naturalized Subterranean Clover Strains in Western Australia: A Preliminary Agronomic Examination," Aust. J. Agric. Res., vol. 18, pp. 713-731 (1967). cited by other.
Herman, C. et al., "Soybean Phytoestrogen Intake and Cancer Risk," American Institute of Nutrition, pp. 7575-7705 (1995). cited by other.
Holt, S., "Selected Bibliography of Scientific Studies on Genistein and Other Soya Isoflavones," Soya for Health: The Definitive Medical Guide, pp. 159-170 (1996). cited by other.
Jenkins, David J.A. et al., "Leguminous seeds in the dietary management of hyperlipidemia," Am. J. Clin. Nut., vol. 38, pp. 567-573 (1983). cited by other.
Joannou, G. E., "A Urinary Profile Study of Dietary Phytoestrogens. The Identification and Mode of Metabolism of new Isoflavonoids," J. Steroid Biochem. Molec. Biol., vol. 54, No. 3/4, pp. 167-184 (1995). cited by other.
Jones, Amanda E. et al., "Development and Application of a High-Performance Liquid Chromatographic Method for the Analysis of Phytoestrogens," J. Sci. Food Agric., vol. 46, pp. 357-364 (1989). cited by other.
Kaldas, Rami S. et al., "Reproductive and General Metaloblic Effects of Phytoestrogens in Mammals," Reproductive Toxicology Review, vol. 3, No. 2, pp. 81-89 (1989). cited by other.
Kelly, Graham, "Standarized Red Clover Extract Clinical Monograph," American Botanical Council, HerbClip, pp. 3-12 (Francis, C.M. et al., "Varietal Variation in the Isoflavone Content of Subterranean Clover: Its Estimation by a Microtechnique,"Aust. J. Agric. Res., 16:557-564 (1965. cited by other.
Kitada, Yoshimi et al., "Determination of Isoflavones in soy bean by high-performance liquid chromatography with amperometric detection," J. Chrom., vol. 366, pp. 403-406 (1986). cited by other.
Kitts, D.D. et al., "Uterine Weight Changes and .sup.3H-Uridine Uptake in Rats Treated with Phytoestrogens," Can. J. Anim. Sci., vol. 60 pp. 531-534 (1980). cited by other.
Knuckles, Benny E., et al., "Coumestrol Content of Fractions Obtained During Wet Processing of Alfalfa," J. Agric. Food Chem., vol. 24, No. 6, pp. 1177-1180, (1976). cited by other.
Kudou, Shigemitsu et al., "A New Isoflavone Glycoside in Soybean Seeds (Glycine max Merrill), Glycitein 7-O-.beta.-D-(6''-O-Acetyl)-Glucopyranoside,"Agric. Biol. Chem., vol. 55, No. 3, pp. 859-860 (1991). cited by other.
Kudou, Shigemitsu et al., "Malonyl Isoflavone Glycosides in Soybean Seeds Glycine max Merrill)," Agric. Biol. Chem., vol. 55, No. 9, pp. 2227-2233 (1991). cited by other.
Lindner, H.R., "Study of the Fate of Phyto-Oestrogens in the Sheep by Determination of Isoflavones and Coumestrol in the Plasma and Adipose Tissue," Aust. J. Agric. Res., vol. 18, pp. 305-333 (1967). cited by other.
Lock, Margaret, "Contested meanings of the menopause," The Lancet, vol. 337 , pp. 1270-1272 (1991). cited by other.
Martin, P.M. et al., "Phytoestrogen Interaction with Estrogen Receptors in Human Breast Cancer Cells," Endocrinology, vol. 193, No. 5, pp. 1860-1867 (1978). cited by other.
Mazur, Witold M., Isoflavonoids and lignans in legumes: Nutritional and health aspects in humans, Nutritional Biochemistry (9-193-200), Elsevier Science Inc. (1998). cited by other.
MediHerb Price List and Order form, Nov. 1990. cited by other.
Messina, Mark et al., "The Role of Soy Products in Reducing Risk of Cancer," J. of National Cancer Institute, vol. 83, No. 8, pp. 541-546 (1991). cited by other.
Morris, P., "Identification and Accumulation of Isoflavonoids and Isoflavone Glucosides in Soybean Leaves and Hypocotyls in Resistance Responses to Phytophthora Megasperma f.sp. Glycinea," Physiological and Molecular Plant Pathology, 39 pp. 229-244(1991). cited by other.
Mowrey, Daniel B. "Next Generation Herbal Medicine," Second Edition/Completely Revised, Guaranteed Potency Herbs, Keats Publishing, Inc., pp. 3-13 (1988). cited by other.
Murphy, P.A., "Phytoestrogen Content of Processed Soybean Products," Food Technology, pp. 60-64 (1982). cited by other.
Murphy, P.A., "Separation of Genistin, Daidzin and Their Aglucones, and Coumesterol by Gradient High Performance Liquid Chromatography," J. Chrom, vol. 211, pp. 166-169 (1991). cited by other.
Naim, M. et al., "A New Isoflavone from Soya Beans," Phytochemistry, vol. 12, pp. 169-170 (1973). cited by other.
Naim, M. et al., "Soybean Isoflavones, Characterization, Determination, and Antifungal Activity," J. Agr. Food Chem., vol. 22, No. 5, pp. 806-810 (1974). cited by other.
Nash, A.M. et al., "Fractionation and Characterization of Alchol Extractables Associated with Soybean Proteins, Nonprotein Components," J. Agr. Food Chem., vol. 15, No. 1, pp. 102-108 (1967). cited by other.
Ohta, Naokazu et al., "Isoflavonoid Constitents of Soybeans and Isolation of a New Acetyl Daidzin," Agric. Biol. Chem., 43, vol. No. 7, pp. 1415-1419 (1979). cited by other.
Okano, Koji et al., "Isolation of Four Kinds of Isoflavon from Soya Bean," Bron: Bull. Agr. Chem. Soc. Japan. 15, vol. 15, p. 110 (1939). cited by other.
Okubo, Kazuyoshi et al., "Components Responsible for the Undesirable Taste of Soybean Seeds," Biosci. Biotech. Biochem., vol. 56, No. I, pp. 99-103 (1992). cited by other.
Pope, G.S., "The Importance of Pasture Plant Oestrogens in the Reproduction and Lactation of Grazing Animals," Dairy Science Abstracts, vol. 16, No. 5, pp. 333-356 (1954). cited by other.
Price, K.R. et al., "Naturally Occurring Oestrogens in Foods--A Review," Food Additives and Contaminants, vol. 2, No. 2 pp. 73-106 (1985). cited by other.
Reinli, Kathrin et al., "Phytoestrogen Content of Food--A Compendium of Literature Values," Nutrition and Cancer, vol. 26, No. 2, pp. 123-148 (1996). cited by other.
Rose, David P., "Dietary Fiber, Phytoestrogens, and Breast Cancer," Nutrition, vol. 8, No. 1 (1992). cited by other.
Rossiter, R.C., "Physiological and Ecological Studies on the Oestrogenic Isoflavones in Subterranean Clover (T. Subterraneum L.,) " Aust. J. Agric. Res., Chapter III, 18:23-37 (1967). cited by other.
Rossiter, R.C., "Physiological and Ecological Studies on the Oestrogenic Isoflavones in Subterranean Clover (T. Subterraneum L.)" Aust. J. Agric. Res., Chapter IV, 18:39-46 (1966). cited by other.
Seo, A. et al., "Improved High-Performance Liquid Chromatographic Analysis of Phenolic Acids and Isoflavonoids from Soybean Protein Products," J. Agric. Food Chem., vol. 32, No. 3, pp. 530-533 (1984). cited by other.
Setchell, K.D.R. et al., "High-Performance Liquid Chromatographic Analysis of Phytoestrogens in Soy Protein Preparations with Ultraviolet, Electrochemical and Thermospray Mass Spectrometric Detection," J. Chrom., vol. 386 pp. 315-323 (1987). citedby other.
Setchell, K.D.R. et al., "Mammalian Lignans and Phyto-oestrogens Recent Studies on their Formation, Metabolism and Biological Role in Health and Disease," in Role of the Gut Flora In Toxicity and Cancer, pp. 315-339 (1988). cited by other.
Setchell, KDR et al., "Nonsteroidal estrogens of dietary orgin: possible roles in hormone-dependent disease," Am. J. Clin. Nut., vol. 40 pp. 569-578 (1984). cited by other.
Shimoyamada, Makoto et al., "Saponin Composition in Developing Soybean Seed (Glycine max(L.) Merrill, cv. Mikuriyaao), " Agric. Biol. Chem., vol. 55, No. 5, pp. 1403-1405 (1991). cited by other.
Shutt, Donald A., "The Effects of Plant Oestrogens on Animal Reproduction," Endeavour, vol. 35, pp. 110-113 (1976). cited by other.
Shutt, D.A. et al., "Free and Conjugated Isoflavones in the Plasma of Sheep Followed Ingestion of Oestrogenic Clover," Aust. J. Agric. Res., vol. 18 pp. 647-655 (1967). cited by other.
Shutt, D.A., "Interaction of Genistein With Oestradiol in the Reproductive Tract of the Ovariectomized Mouse", Endrocrin, vol. 37, pp. 231-232 (1967). cited by other.
Shutt, D.A. et al., "Quantitative Aspects of Phyto-Oestrogen Metabolism in Sheep Fed on Subterranean Clover (Trifolium Subterraneum Cultivar Clare) or Red Clover (Trifolium Pratense)," Aust. J. Agric. Res. vol. 21, pp. 713-722 (1970). cited by other.
Shutt, D.A. et al., "The Significance of Equol in Relation to the Oestrogenic Responses in Sheep Ingesting Clover With a High Formononetin Content," Aust. J. Agric. Res.vol. 19, pp. 545-553 (1968). cited by other.
Shutt, D.A. et al., "Steroid and Phyto-Oestrogen Binding to Sheep Uterine Receptors In Vitro," J. Endocr., vol. 52, pp. 299-310 (1972). cited by other.
Smith, G.R. et al., "Influence of Harvest Date, Cultivar, and Sample Storage Method on Concentration of Isoflavones in Subterranean Clover," Crop Science, vol. 26, pp. 1013-1016 (1986). cited by other.
Trease, G.E. et al., "Pharmacognosy," 12.sup.th Ed., pp. 242-260 (1983). cited by other.
Verdeal, Kathey et al., "Naturally-Occurring Estrogens in Plant Foodstuffs--A Review," J. Food Protect., vol. 42, No. 7, pp. 577-583 (1979). cited by other.
Walter, E.D., "Genistin ( an Isoflavone Glucoside) and its Aglucone, Genistein, from Soybeans," J. Am. Chem. Soc., vol. 63, p. 3273 (1941). cited by other.
Wang, G. et al., "A Simplified HPLC Method for Determination of Phytoestrogens in Soybean and Its Processed Products," J. Agr. Food Chem., vol. 38, No. 1, pp. 185-190 (1990). cited by other.
White, Edmund et al., "Extracta," Pharmacopedia, 2d ed. pp. 166-167 (1909). cited by other.
Wilcox, G. et al., "Oestrogenic effects of plant foods in post-menopausal women," British Med. J., vol. 301, pp. 905-906 (1990). cited by other.
Wong, E., "Detection and Estimation of Oestrogenic Constituents in Red Clover," J. Sci. Food Agric., vol. 13, pp. 304-308 (1962). cited by other.
Wong, E., "The Oestrogenic Activity of Red Clover Isoflavones and Some of Their Degradation Products," J. Endocrin., vol. 24, pp. 341-348 (1962). cited by other.
"Estrogenic Activity in Plants," Brisbane Seminar (Summary of Talk by Nancy Beckham) (1985). cited by other.
"Phenolic Constituents," Soybeans: Chemistry and Technology, vol. 1, pp. 186-189 (1972). cited by other.
"Solvent Treatment of Beans and Fractions," Soybeans: Chemistry and Technology, p. 149 (1972). cited by other. |
|
| Abstract: |
Compositions enriched with natural phyto-oestrogens or analogues thereof selected from Genistein, Daidzein, Formononetin and Biochanin A. These may be used as food additives, tablets or capsules for promoting health in cases of cancer, pre-menstrual syndrome, menopause or hypercholesterolaemia. |
| Claim: |
I claim:
1. A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease.[.,.]. .Iadd.or .Iaddend.cancer of the prostate,.[.or elevated blood cholesterol,.]. said method comprising administering to a subject having said condition or predisposed to said condition to a therapeutically effective amount of a health supplement composition comprising an extract from soya orclover, said composition comprising any two or more .[.phyto-estrogens.]. .Iadd.phyto-oestrogens .Iaddend.of the group Genistein, Daidzein, Biochanin A, Formononetin or the natural glycosides of any of said .[.phyto-estrogens.]. .Iadd.phyto-oestrogens.Iaddend..
2. A method according to claim 1, wherein said composition is administered for treating benign breast disease.
3. The method according to claim 1, wherein said .[.phyto-oestrogen is.]. .Iadd.phyto-oestrogens are .Iaddend.extracted from soy.
4. The method according to claim 3, wherein said .[.phyto-oestrogen is.]. .Iadd.phyto-oestrogens are .Iaddend.extracted from soy hypocotyls.
5. A method according to claim 1, wherein said .[.phyto-oestrogen consists.]. .Iadd.phyto-oestrogens consist .Iaddend.essentially of .Iadd.(.Iaddend.a) genistein and .Iadd.(.Iaddend.b) daidzein component, wherein component .Iadd.(.Iaddend.a)optionally contains biochanin A, and component .Iadd.(.Iaddend.b) optionally contains formononetin, and the ratio of .[.a):b).]. .Iadd.(a) to (b) .Iaddend.is about 1:2 to 2.1.
6. The method according to claim 1, wherein .[.the phyto-oestrogen is.]. .Iadd.said phyto-oestrogens are .Iaddend.administered in an amount of from about 20 mg to 200 mg per day.
7. The method according to claim 1, wherein .[.the phyto-oestrogen is.]. .Iadd.said phyto-oestrogens are .Iaddend.administered in an amount of from about 50 mg to 150 mg per day.
8. The method according to claim 1 whereby .[.the phyto-oestrogen is.]. .Iadd.said phyto-oestrogens are .Iaddend.administered at least daily, over a period of at least a month.
.[.9. A method according to claim 1, wherein said composition is administered for treating or reducing the predisposition to elevated levels of cholesterol in the blood stream..].
10. A method according to claim 1, wherein said composition is administered for treating cancer of the prostate.
11. A pharmaceutical preparation, in solid dosage unit form, .[.the.]. .Iadd.having a .Iaddend.biologically active component .[.of said preparation.]. .Iadd.comprising phyto-oestrogens .Iaddend.consisting essentially of .[.any two or moreconcentrated, phytoestrogen-derived isoflavones selected from the group consisting of Genistein, Daidzein, Biochanin A, Formononetin.]. .Iadd.(a) genistein component and (b) daidzein component, wherein component (a) optionally contains biochanin A, andcomponent (b) optionally contains formononetin, .Iaddend.or the natural glycosides of .[.any of.]. said .[.phytoestrogens and.]. .Iadd.phyto-oestrogens, and wherein the ratio of (a) to (b) is about 1:2 to 2:1, .Iaddend.said preparation including apharmaceutically acceptable carrier.
12. A pharmaceutical preparation, as claimed in claim 11, wherein said solid dosage unit is selected from the group consisting of a pill, tablet, coated tablet, capsule or powder.
13. A pharmaceutical preparation, as claimed in claim 12, wherein said .[.isoflavone is.]. .Iadd.phyto-oestrogens are .Iaddend.present in said solid dosage unit in an amount from about 20 mg.[...]. to about 200 mg.[...]. per dosage unit.
.Iadd.14. The pharmaceutical preparation according to claim 11, wherein said phyto-oestrogens are extracted from soy. .Iaddend.
.Iadd.15. The pharmaceutical preparation according to claim 14, wherein said phyto-oestrogens are extracted from soy hypocotyls. .Iaddend.
.Iadd.16. A method for treating or reducing the predisposition to a condition selected from the group consisting of benign breast disease, cancer of the prostate, or elevated blood cholesterol, said method comprising administering to a subjecthaving said condition or predisposed to said condition a therapeutically effective amount of a health supplement composition comprising an extract from soy or clover, said composition comprising phyto-oestrogens, wherein the phyto-oestrogens consistessentially of (a) genistein and (b) daidzein, wherein component (a) optionally contains biochanin A, and component (b) optionally contains formononetin, wherein the ratio of (a) to (b) is about 1:2 to 2:1. .Iaddend.
.Iadd.17. The method according to claim 16, wherein said phyto-oestrogens are administered in an amount of from about 20 mg to 200 mg per day. .Iaddend.
.Iadd.18. The method according to claim 16, wherein said phyto-oestrogens are administered in an amount of from about 50 mg to 150 mg per day. .Iaddend.
.Iadd.19. The method according to claim 16 wherein said phyto-oestrogens are administered at least daily, over a period of at least a month. .Iaddend. |
| Description: |
TECHNICAL FIELD
This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen metabolites, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietaryadditive, for example.
BACKGROUND ART
The particular product in accordance with the invention is an extract of certain plants with the particular purpose of enrichment for phyto-oestrogens, both in their natural state and their closely related derivatives and metabolites.
Plants which are used as foodstuffs or medicinal herbs contain a wide variety of chemicals which are assimilated into the body following ingestion. Some of these chemicals are important nutrients for man and animals (e.g. fats, carbohydrates,proteins, vitamins, minerals) while others have none, or little or no known nutritional value. The phyto-oestrogens hitherto have fallen into this latter category of no known nutritional value.
There are 3 principal classes of phyto-oestrogens, viz. isoflavones, lignans, and coumestans. The isoflavones are thought to have a broad range of biological functions in plants, although these are poorly understood. However, two particularfunctions are recognised--(a) as phyto-alexin or stressor chemicals which are secreted by the plant in response to attack by parasites such as insects, fungi, viruses, etc. and which display activity against these parasites, and (b) chemicals whichencourage colonisation of nitrogen-fixing bacteria on the roots of legumes. The biological functions in plants of the lignans and coumestans is not generally understood.
The different types of phyto-oestrogens are as follows.
Type 1 phyto-oestrogens--(isoflavones)
Isoflavones appear to be widely distributed in the plant kingdom and over 700 different isoflavones are described. However, the isoflavones which display oestrogenic activity belong to a small sub-group and are restricted almost exclusively tothe Leguminosae family. The known oestrogenic isoflavones are daidzein, formononetin, genistein and biochanin A. In common human foodstuffs such as soya, chickpeas, lentils and beans, the total levels of the oestrogenic isoflavones range between about40 and 300 mg per 100 g dry weight.
In the raw plant material, isoflavones occur principally as glycosides. Following ingestion by man and animals, the glycoside moiety is hydrolysed free by a combination of gastric and hydrolysis and fermentation by intestinal bacteria. Some ofthe isoflavones in the algucone form are absorbed directly and circulate in the blood, while the remainder are metabolised by intestinal fermentation to a variety of compounds which are also absorbed. The absorbed isoflavones and their metabolitesappear to undergo little or no further metabolism in the body, being readily transported in the bloodstream, and ultimately being excreted in the urine.
Type 2 phyto-oestrogens (lignans).
Lignans are widely distributed in the plant kingdom. Over one hundred lignans are described and they are reported in common human foodstuffs such as cereals, fruits and vegetables. Oilseeds such as flax (linseed) have the highest known levelsat 20-60 mg/100 g dry weight, while cereals and legumens have much lower levels at 0.3-0.6 mg/100 g, and vegetables even lower levels at 0.1-0.2 mg/100 g. The most common lignan described is metairesinol. Dietary lignans also appear to be metabolisedfairly efficiently within the gut by bacterial fermentation, yielding metabolites such as enterodiol and enterolactone which are absorbed into the bloodstream and excreted in the urine.
Type 3 phyto-oestrogens (coumestans).
Compared to isoflavones and lignans, oestrogenic coumestans appear to have a relatively restricted distribution in plants and generally occur at much lower levels. Alfalfa, ladino clover and some other fodder crops such as barrel medic may havesignificant levels and have been reported to cause reproductive dysfunction in grazing animals. In the human diet, the important sources of coumestans are sprouts of soya and alfalfa where levels up to 7 mg/100g dry weight are reported. Whole soyabeansand other common foodstuff legumes contain levels of approx. 0.12 mg/100 g dry weight and most of that is concentrated in the seed hull which commonly is removed in the preparation of human foodstuffs.
Type 4 phyto-oestrogens (oestrogens).
These are compounds closely related to animal oestrogens such as oestrone, oestradiol and oestriol. These have been described in plants such as liquorice, apple, French bean, pomegranate and date palm. Little is known of the metabolism andbiological significance of these chemicals in humans and animals.
The full range of biological effects in animals of these dietary phyto-oestrogens has received only recent study. A primary effect appears to be associated with their close structural relationship to naturally-occurring oestrogens which allowsthe phyto-oestrogens to mimic the effects of the endogenous oestrogens. The known biological effects of phyto-oestrogens can be summarised thus:
In vitro:
(a) bind to both cytoplasmic and nuclear membrane (Type II) oestrogen receptors on human tissues; (b) strongly compete with oestrogens for oestrogen receptors, but only weakly stimulate those receptors; (c) strongly stimulate the production ofsex hormone-binding globulin (SHBG) from human cells; In vivo (d) weakly oestrogenic in animals; (e) competitively-inhibit the response of tissue to oestrogens.
The three major types of phyto-oestrogens appear to act at the cellular level in a similar manner, that is through interaction with cell surface oestrogen receptors. In the body, naturally-occurring oestrogens circulating in the blood largelyexert their activity by interaction with oestrogen receptors on cell surfaces; such interactions then triggering a particular biological function of that particular cell. Phyto-oestrogens are able to bind to those oestrogen receptors because thestructure of these compounds so closely resembles the endogenous oestrogens, but unlike the animal oestrogens, phyto-oestrogens only weakly activate the oestrogen receptor.
As a result of phyto-oestrogens and endogenous oestrogens competing for the oestrogen-binding sites on the cells, the more weakly oestrogenic phyto-oestrogens can be considered to have an anti-oestrogenic effect. This phenomenon is known ascompetitive-inhibition, by which is meant that the biological effect of an active substance is impaired by the competitive binding to a target receptor of a similar but less active compound.
Thus a primary biological effect of phyto-oestrogens is held to be competitive inhibition of endogenous oestrogens. However, another more direct effect is the stimulation of synthesis of SHBG in the liver, as occurs with orally administeredsynthetic steroidal oestrogens. High levels of dietary phyto-oestrogens are thought to be responsible for the higher SHBG levels seen in vegetarians and in cultures maintaining traditional (high legume-containing) diets.
At high levels, dietary phyto-oestrogens can have profound physiological effects. An example of this is sheep and cattle gazing pastures containing a high proportion of subterranean clover or red clover which can contain levels ofphyto-oestrogens as high as 5% of the dry weight of the plant. As a result of the competitively-inhibitory effect of the dietary phyto-oestrogens on endogenous oestrogen function in the hypothalamus, male and female sheep and cows can develop androgenicsymptoms.
Such high dietary levels of phyto-oestrogens, however, are rare. It is far more common that most animal and human diets contain low to moderate levels of phyto-oestrogens, and there is growing epidemiological evidence that such levels have abeneficial effect on human health.
In most traditional human diets in developing countries, the principal phyto-oestrogens consumed are isoflavones because of the generally high reliance on legumes (also known as pulses) as a source of protein. The general consumption rates(g/day/person) for legumes for different regions currently are approximately: Japan (50-90), India (40-80), South America (30-70), North Africa (40-50), Central/Southern Africa (20-50) and Southern Mediterranean (30-60). Legumes also are a source oflignans and, to a much lesser extent, coumestans, and the additional cereal and vegetables in the diet would also boost the lignan intake. However, the isoflavone intake in these traditional cultures with high legume consumption would typically be muchin excess of either lignan or coumestan intake.
The major types of legumes used in traditional diets include soya, chickpeas, lentils, ground nuts, beans (e.g. broad, haricot, kidney, lima, navy), and grams (bengal, horse and green).
In Western, developed countries, the daily intake of dietary phyto-oestrogens generally is negligible to low. In Western Europe, North America and Australasia, legumes were a major source of protein for the majority of the populations up to theend of the 19th century. From that time, legume consumption has declined significantly, being replaced in the diet with protein of animal origin. Average legume consumption in these regions currently is between 5-15 g/day/person with a significantproportion of the population ingesting little or no legumes or other phyto-oestrogen containing foods on a regular basis. Moreover, the types of legumes consumed in these regions (e.g. garden peas, French beans) have a typically lower isoflavone contentthan legumes such as soya and chick peas.
Based on the typical consumption rates and types of foodstuffs consumed, the typical phyto-oestrogen intake (mg/day) for different regions can be calculated approximately as
TABLE-US-00001 Isoflavones Lignans Coumestans Japan 50-300 2-5 0.5 Australia 2/25 1-5 0.2
Thus it can be seen that regions which have maintained traditional diets have a higher average daily intake of phyto-oestrogens, particularly isoflavones, compared to western countries. People in communities such as Japan or developing countrieswith high legume intake excrete substantially higher phyto-oestrogen metabolites in their urine compared to people in Western countries. Within the latter, vegetarians also excrete higher phyto-oestrogen metabolite levels than do those consuming a moretypical, omnivorous Western diet.
The presence of relatively large amounts of phyto-oestrogen metabolites in urine serves to highlight their potential biological significance. It has been shown that total urinary excretion of isoflavones and their active metabolites in peopleconsuming moderate amounts of legumes is greatly in excess (up to 10,000.times.) of steroidal oestrogen levels. So that while the oestrogenicity of isoflavones to oestrogen receptors is only about 1% that of endogenous oestrogens, this weaker effect isoff-set by the much higher blood levels of the isoflavones.
It is known that legumes have formed an important part of the human diet over the past 20,000-30,000 years. It therefore follows that human metabolism has evolved over at least this period in the presence of relatively large levels of dietaryphyto-oestrogens, particularly isoflavones. Given the known biological effects of phyto-oestrogens, it also follows that endogenous oestrogen metabolism and function has evolved in the face of significant competitive inhibiting effects ofphyto-oestrogens. It has been speculated that the presence of significant dietary levels of phyto-oestrogens in recent human evolution has led to a degree of adaption by tissues responsive to reproductive hormones to these dietary components. That is,both the rate of production and/or the function of endogenous oestrogens may be either dependent upon or influenced by the presence of phyto-oestrogens in the body. It follows therefore that a relative deficiency of dietary phyto-oestrogens could beexpected to lead to an imbalance of endogenous oestrogen metabolism.
There is increasing interest in the likely contribution of a relative deficiency of dietary phyto-oestrogens to the development of the so-called "Western diseases", especially cancer of the breast, benign (cystic) breast disease, cancer of theuterus, cancer of the prostate, cancer of the bowel, premenstrual syndrome, menopausal syndrome, and atherosclerosis. All of these diseases are associated to a greater or lesser extent to oestrogen metabolism, and oestrogen function is either known oris suspected to play a role in their aetiology and/or pathogenesis.
Each of these diseases occurs at much higher incidence in Western, developed countries than it does in developing communities. Moreover, it is thought that in Western communities, the incidences of each have risen over the past century. It isalso generally held, that of all the environmental factors likely to be contributing to this phenomenon, diet is the principal factor. Of those dietary components with the potential to influence the aetiology of oestrogen-related disease, there is agrowing awareness that phyto-oestrogens may have important potential.
The beneficial effects of phyto-oestrogens on human health are thought to derive from at least two principal function, those being (i) competitive-inhibition of the function of endogenous oestrogens, and (ii) the stimulation of production ofSHBG. SHBG plays an important role in primates in binding and transporting the reproductive hormones (oestrogens, androgens) in blood so that the availability of reproductive hormones is regulated to a large degree by SHBG levels. Higher SHBG levelsare considered beneficial in leading to a reduction in both blood levels of unbound (and unregulated) reproductive hormones and metabolic clearance rates of the hormones. Although isoflavones are potent stimulators of SHBG synthesis, they only weaklybind to SHBG, so that the increased SHBG levels resulting from the dietary isoflavones are largely available for binding to endogenous oestrogens.
In terms of directly identifying the beneficial effects of phyto-oestrogens in amelioration of any or all of the "Western diseases" there are only two examples. In one example, the diets of women, with menopausal syndrome were supplemented withfoodstuffs (soya, linseed, red clover) high in phyto-oestrogens, and an alleviation of menopausal symptoms to an extent similar to that obtained with replacement therapy with synthetic oestrogens was achieved; that effect was ascribed to thephyto-oestrogen content of the supplement. In the other example, legumes such as soya and various pulses have been shown to have a hypocholesterolaemic effect in humans; this effect has not been ascribed to phyto-oestrogens, although purifiedisoflavones do have a hypocholesterolaemic effect in animals with artifically-induced hypercholesterolaemia.
In summary, it could reasonably be deduced that the inclusion of greater levels of foodstuffs high in phyto-oestrogens in the standard diets of men and women in developed countries could be expected to redress a general imbalance of endogenousreproductive hormone metabolism, thereby reducing the predisposition of those communities to the above diseases. While there are various types of phyto-oestrogens which may be suitable to this end, the large discrepancy in isoflavone consumption betweencommunities with Western and traditional diets suggest that foodstuffs with high isoflavone content are of prime interest.
However it is unrealistic to expect that public education programmes would readily convert communities in developed countries from a diet where the protein content is predominantly animal-derived, to one where the protein is predominantlylegume-derived. Moreover, the legumes which are commonly consumed in developed countries are relatively poor sources of phyto-oestrogens and the general acceptance in the community of less well-known legumes with higher phyto-oestrogen content would benecessarily a slow process. Also, the highly variable levels of phyto-oestrogens in foodstuffs relating to plant strain type, degree of plant maturity, and climatic and other environmental conditions suggests that the supply of an assured amount ofphyto-oestrogens through the use of whole foodstuffs may be difficult.
An alternative strategy it to make available either (i) phyto-oestrogens in a purified form, or (ii) foodstuffs which are enriched for phyto-oestrogens. In this way, the phyto-oestrogen could be added to the diet in a convenient form as asupplement without requiring any substantive change to the diet.
DISCLOSURE OF INVENTION
The present invention concerns a health supplement specifically enriched for isoflavones selected from genistein, daidzein, formononetin and biochanin A, or their natural glycoside form, or their analogues, in sufficient amounts to improve thehealth of a human.
Preferably the supplement contains an excipient, a diluent, a carrier or the like, or else the supplement is mixed with food or can be consumed directly. It is also preferred that foodstuffs, are readily available, have no known toxiccomponents, and are rich sources of isoflavones; such foodstuffs preferably being red clover or soya. It is also preferred that the ratio of genistein and/or it methylated derivative biochanin A to daidzein and/or its methylated derivative formononetinis between 1:2 to 2:1. Other plant components with oestrogenic activity including lignans, coumestans and flavones may also be present in the extract, but is held that these are of secondary importance to the predominant isoflavones. The termphyto-oestrogens is used hereafter to indicate a predominance of isoflavones with lesser amounts of lignans, coumestans and flavones.
The invention also concerns a method of improving the health of a human by administering to the human a sufficient amount of phyto-oestrogen. Ideally, the phyto-oestrogen is administered regularly on a daily basis over a sufficient period suchas at least a month. The health conditions which may be prevented or ameliorated include cancer of the breast, cancer of the prostate, cancer of the uterus, cancer of the bowel, benign (or cystic) breast disease, pre-menstrual syndrome (also known aspre-menstrual tension), or adverse symptoms associated with menopause in women. The method and supplement in accordance with the invention also improves the health of a human having elevated levels of blood cholesterol. The product also is useful inavoiding or ameliorating cancer in persons. The symptoms produced by these conditions and the general well-being is also improved by the use of these supplements.
The phyto-oestrogen in accordance with the invention may be obtained from a number of different sources. Preferably the phyto-oestrogens are extracted from a clover such as red clover or subterranean clover or from soya which contain high levelsof phyto-oestrogens. However, any source rich in phyto-oestrogens may be used instead, if desired.
Various different isoflavones have been identified from these sources--they are principally genistein, biochanin A, daidzein, formononetin and glyciten. In plants these compounds occur principally in a glycoside form bound to sugars such asglucose, with smaller amounts present as the aglucone forms. The formulae of the isoflavones are: ##STR00001##
The structure of biochanin A is the same as for genistein but with a 4'-methoxy group, and similarly formononetin has the same structure as daidzein, but with a 4'-methoxy group.
Following ingestion by humans, the glycosidic isoflavones are hydrolysed to the aglucone form and biochanin A and formononetin are demethylated by bacterial fermentation to genistein and daidzein respectively. A small proportion of these freeisoflavones are absorbed directly from the bowel and circulate in the blood. The bulk of the isoflavones, however, remain in the bowel and undergo fermentation to form various metabolites which also are absorbed into the bloodstream. The principalmetabolites which have been identified are equal to O-desmethylangolensin.
In vitro and in vivo studies have indicated that genistein, biochanin A, equol, daidzein, formononetin all have oestrogenic activity in descending order. O-desmethylangolensin is only very weakly oestrogenic and glycitein is non-oestrogenic
In animal and in vitro studies, genistein has been shown to have greater oestrogenic/anti-oestrogenic activity and SHBG-stimulating capacity than the other isoflavones or their metabolites (approximately 10 times that of daidzein andformononetin). However, the full range of biological effects of the different isoflavones have yet to be fully determined, and in particular their relative efficacies in the different biological effects such as oestrogenicity, hypocholesterolaemia,anti-anglogenesis, anti-oxidation, anti-carcinogenesis for example are not yet fully known.
It is thought that because the methyl forms (biochanin A and formononetin) ultimately are largely demethylated to their principals, genistein and daidzein, with improved biological efficacy, then it is unimportant whether the isoflavones arepresent in the claimed product in the methylated or demethylated forms.
Given that the relative biological importance of the two isoflavone groups (being genistein and daidzein) to human health remains unclear, and that each might indeed have different importance, plus the fact that both isoflavones are present inthe diet in approximately equal proportions, then it is prudent that both isoflavones be present in the claimed product in approximately equal proportions.
Any leguminous plants such as detailed here could be used as sources of phyto-oestrogens (principally isoflavones with lesser amounts of lignans and coumestans): Indian liquorice (Abrus precatorius); various species of Acacia spp. including, A.aneura, A. cibaria, A. longifolia, and A. owaldii; ground nut (Apio tuberosa); ground pea (Arachis hypogea); milk vetch (Astragalus edulis); marama bean (Bauhinia esculenta); sword bean (Cajanus cajan indicus); jack bean (Canavalia ensiformis); swordbean (Canavalia gladiata); seaside sword bean (Canavalia rosea); various Cassia spp. including C. floribunda, C. laevigata, and C. occidentalis; carobbean (Ceratonia siliqua); chick pea (Cicer arietinum); yebnut (cordeauxia edulis); various Crotalariaspp. including C. laburnifolia, and C. pallida; cluster bean (Cyamopsis psoralioides); tallow tree (Detariaum senegalense); sword bean (Entada scandens); balu (Erythrina edulis); soyabean (Clycine max;) inga (Ingaedulis); Polynesian chestnut (Inocarpusfagifer); hyacinth bean (Lablab purpureus); grass pea or Indian vetch (Lathyrus sativus); cyprus vetch (Lathyrus ochrus); lentil (Lens culinaris); jumping bean (Leucaenal eucocephala); various Lupinus spp. including L. albus, L. luteus, L.angustifolium, L. mutabilis, and L. cosentiniij; ground bean (Macotylma geocarpa); horse gram (Macrotyloma uniflorum): alfalfa (Medicago sativa); velvet bean (Mucuna prureins); yam beans (Pachyrhyzuz erosus, P. tuberosus); African locust bean (Parkiaclappertoniana); Parkia speciosa; oil bean tree (Pentaclethra macrophylla); various Phaseolus spp. including P. acutifolius, P. vulgaris, P. luntus, P. coccineus, P. adenathus, P. angulris, P. aureus, P. calcaratus, P. mungo, and P. polystachyus; gardenpea (Pisum sativum); djenko bean (Pithecolobium lobatum); mesquite (various Prosopis spp.); geo bean (Psophocarpus scandens, P. tetragonolobus); various Psoralea spp.; Sesbania bispinosa; yam bean (Sphenostylis stenocarpa); tamarind (Tamarindus indica);fenugreek (Trigonella foenumgraecum); vetches (various Vivia spp. including V. sativa, V. atropurpurea, V. ervilia, and V. monantha); broad bean (Vicia faba); black gram (Vigna mungo); various Vigna spp. including V. radiata, V. aconitifolia, V.adanatha, V. angularus, V. tribolata, V. umbelata, and V. unguiculata; and earth pea (Voandzeia subterranea).
The ideal sources of phyto-oestrogens for preparation of a supplement in accordance with the invention are preferably those which (i) are readily available, (ii) are relatively inexpensive, (iii) are readily and economically processed so as toyield the extract, (iv) have a high isoflavone content so as to provide high yields, and (v) have no known toxic components requiring selective removal or inactivation.
Certain clovers, such as red clover (T. pratense) and subterranean clover (T. subterranean) are the preferred sources. On a dry weight basis, these clovers contain the highest amounts of oestrogenic isoflavones of all legumes tested to date withlevels of 3-5 g % (T. subterranean) and 1-3 g % (T. pratense). In comparison, soya flour has a level of 0.15-0.30 g %, lentils (0.08-0.12 g %), chick peas (0.07-0.13 g %), and garden peas (0.02-0.03 g %). Thus it can be seen that clovers containapproximately at least 10-30 times by weight the isoflavone content of other commonly available, human leguminous foodstuffs meaning that for manufacturing purposes, the yield of isoflavones per unit weight of plant material is many times greater fromclover than from other legumes.
Red clover and subterranean clover also are common fodder crops and are readily grown and are widely available. Clovers also are comparatively cheaper ($200/tonne) than crops such as soya and lentils ($500/tonne).
With clovers, the isoflavones are recovered from the leaf rather than from the seed in the case of soya, beans, nuts and grams. This provides a substantially higher yield of isoflavones per unit area of pasture for clovers compared to otherlegumes because of the greater leaf matter compared to seed matter recovered per plant.
Clovers also have an extended growing season, and faster growth rates compared to those legumes such as soya, lentils or chick peas where the seed is the end-product. Clover can be cropped for its leaf content repeatedly over a single growingseason. An additional benefit of this is that as phyto-alexins, the isoflavones content increases in response to the stress of cropping.
Thus it can be seen that in clovers versus other legumes provide a combination of (a) higher isoflavone content per dry weight of plant, (b) a higher yield of dry matter containing isoflavones per plant, and (c) a higher yield of dry matter perhectare.
An additional feature of clovers is that there are wide varieties of cultivars with widely differing isoflavone levels and types. This allows blending of different cultivars to achieve the desired ratio of the different isoflavones, although itis equally possible to use a single cultivar which provides the desired ratio.
Other legumes such as soyabean flour may be used for enrichment of phyto-oestrogens but the substantially poorer (approx. 10%) yield of isoflavones compared to clovers means that the manufacturing costs are substantially greater and there issubstantially greater amounts of waste products which requires disposal or further treatment for re-use as a foodstuff. An alternative, however, to the use of whole soya for this purpose, is to use the hull, and hypocotyl (or germ) of the hole soyabean. The hull and hypocotyl represent only a small proportion by weight (8% and 2% respectively) of the intact bean. However, the coumestrol content of soya is concentrated in the hull, and the daidzein content of soya is concentrated in the hypocotyl. Thetwo cotyledons which comprise the bulk of the soyabean (90% by weight) contain the bulk of the genistein content of soya. During standard processing of soyabeans, the hulls being a fibrous component with little or no perceived nutritional value normallyare separated and removed by physical means. The hypocotyls become separated following the splitting of the cotyledons, and while these currently generally are not deliberately isolated, they may be separated and isolated by passing the disturbedsoyabeans over a sieve of sufficient pore size to selectively remove the small hypocotyl. The hypocotyl contains approx. 1.0-1.5 g % isoflavones (95% daidzein, 5% genistein). The raw hypocotyl and hull material can be ground or milled to produce, forexample, a dry powder or flour which then could be either blended or used separately by a dietary supplement in a variety of ways including, for example, as a powder, in a liquid form, in a granulated form, in a tablet or encapsulated form, or added toother prepared foodstuffs. Alternatively, it could be further processed to yield an enriched extract of phyto-oestrogens. Either or both of these materials also could be added to other leguminous material such as clover to provide the invention.
In plants, the oestrogenic isoflavones are restricted principally to the leaf, fruit and root; the stem and petiole contain very little. With soya and other common human legume foodstuff crops, the leaves are rarely regarded as foodstuff, indeedwith these crops, the plants normally are allowed to die and dry out before the seed crop is harvested. Nevertheless, the fresh leaves of these crops could be regarded as a source of phyto-oestrogens for the invention although the much lower isoflavonecontent of the leaves of these crops compared to clovers, plus their generally slow growth compared to clovers, suggests that they would not be a preferred source of large-scale isoflavone enrichment.
To provide a similar amount of isoflavone to that contained in most traditional legume-rich diets (50-100 mg oestrogenic isoflavones/day) would require an average daily consumption of 3-6 g dry weight or 15-30 g wet weight of specially selectedcultivars of clover with particularly high isoflavone levels. Clover grasses generally are not eaten by humans, except to a limited extent as sprouts of some of the pleasanter testing varieties. Isoflavones are intensely astringent and are responsiblein large part for the bitter taste of legumes. Thus the types of bean sprouts, clover sprouts and alfalfa sprouts generally available have been selected on the basis of cultivar and of age for pleasant taste, and in so doing inadvertently have beenselected for low isoflavone content. Of the sprouts currently available in Western countries for human consumption, between approx. 100-250 g would need to be consumed daily to provide a dosage of 50-100 mg isoflavones. Certainly clovers and otherlegume sprouts are not generally eaten in such sufficient quanitites by humans to obtain the advantages of the present invention.
The invention also concerns formulations containing the phyto-oestrogens discussed above together with a dietary suitable excipient, diluent, carrier, or with a food. Ideally the formulation is in the form of a pill, tablet, capsule, or similardosage form.
The formulations may be a variety of kinds, such as nutritional supplements, pharmaceutical preparations, vitamin supplements, food additives or foods supplemented with the specified active phyto-oestrogens of the invention, liquid or solidpreparations, including drinks, sterile injectable solutions, tablets, coated tablets, capsules, powders, drops, suspensions, or syrups, ointments, lotions, creams, pastes, gels, or the like. The formulations may be in convenient dosage forms, and mayalso include other active ingredients, and/or may contain conventional excipients, carriers and diluents. The inclusion of the subject phyto-oestrogens in herbal remedies and treatments is also a preferred part of the invention.
The invention is also directed to the amelioration, prevention, or of various conditions responsive to treatment with the phyto-oestrogen substances of the invention. The preferred amounts to be administered to the human fall within 20-200 mg ona daily basis. More preferably the dosage is from 50-150 mg on a daily basis, and most preferably at a dosage of about 100 mg. If desired greater dosages can be administered for therapeutic reasons. In contrast to prior practices such high dosageswere not possible. For example, dosages of up to or greater than 1000 mg may be suitable to treat some conditions. In order to obtain the benefits of the invention, the treatment with the isoflavones should continue for a considerable period, ideallyfor at least a month, and ideally continuously for the whole period for which the heatlh improvement advantages should accrue.
The product according to the present invention yields a constant and accurately known amount of isoflavones. The product is also ideally a natural product, which has advantages for consumer acceptance, and in accordance with the supposed theorybehind the invention may very possibly be one of the main causes for its beneficial effects. Whole legumes have a widely variable isoflavone content due to two main causes: the type of legume and the environmental effect. The type of legume typicallyhas a wide range of isoflavone content. The miligram of isoflavone per hundred gram of whole foodstuff (dry weight) is given in the following table.
TABLE-US-00002 Soya Products Whole Soya 150-300 Soya Milk 25-40 (mg per 200 ml) Tofu 55-95 Lentils 80-120 Chickpeas 70-130 Broad beans 15-20 Garden peas 15-25
Thus common leguminous foodstuffs consumed in Western countries (broad beans, garden peas etc.) have relatively low oestrogenic isoflavone content and exceptionally large amounts of these would need to be consumed daily to approximate thoseisoflavone levels consumed in traditional diets. Most Western cultures do not traditionally eat legumes with high isoflavone contents, and those soya products (milk, tofu etc.) which are becoming increasingly popular in Western countries, also haverelatively low isoflavone levels compared to whole soya, indicating that relatively large amounts of these would need to be consumed on a regular basis to deliver to the required isoflavone levels.
The environmental effect arises because the isoflavone levels in any species of plant depend generally on the age of the plant, the climatic conditions where it is grown, the fertiliser and so forth. Therefore constant and consistent dosage isvery difficult with ordinary whole foodstuffs. The accurately determined quality and quantity of the active isoflavones in the product, and its easy consumability when compared with the almost impossible task of eating huge amounts of often practicallyinedible foods, is therefore an important feature of the invention for preventing and helping in overcoming various health problems.
Among the various health problems, the treatment or prevention of high blood cholesterol levels, and the treatment of PMS and menopausal symptoms is especially important. The product of the invention modulates the production and/or function ofendogenous sex hormones in humans to modify or produce health improving effects, including the following: (i) lowered levels of various blood liproproteins including, for instance, low-density and very-low-density cholesterol leading to reduced risk ofdevelopment of atherosclerosis, (ii) reduced risk of development of cancer of the prostate; (iii) reduced risk of cancer of the breast; (iv) reduced risk of development of cancer of the uterus; (v) reduced risk of development of cancer of the largebowel; (vi) reduced risk of development of the syndrome in women commonly referred to pre-menstrual syndrome (PMS), which includes pre-menstrual tension (PMT); (vii) reduced risk of development of many untowed symptoms (including dry vagina, peripheralflushing, depression etc.) commonly associated in women with menopause; and for treating benign breast disease in women (benign or cystic breast disease associated with non-malignant swelling and tenderness of breast tissue). The invention therefore isdirected to a method for the prophylaxis or treatment of a human, to combat conditions associated with phyto-oestrogen deficiency, which comprises administering to the human an effective amount of phyto-oestrogen principally isoflavone but which mightalso include relatively smaller amounts of lignans and coumestans, ideally in a concentrated form, wherein the isoflavones include genistein, and/or biochanin A, and/or daidzein, and/or formononetin.
Cancer of the breast generally is considered to be associated with oestrogenic dysfunction. Breast cancer cells may display more oestrogen receptors than normal breast cells and stimulation of these receptors by endogenous oestrogens is thoughtto be a prime source of stimulation of their malignant growth. Currently synthetic anti-oestrogens are being used to prevent or treat the growth of malignant breast cells. Isoflavones are potent anti-oestrogens that could be expected to help prevent orto successfully treat breast cancer. It has been reported that the risk of breast cancer in western societies is indirectly proportional to the level of phyto-oestrogens in the diet and to the amounts of phyto-oestrogen metabolities excreted in theurine.
Cancer of the prostate generally is considered to be associated with sex hormone dysfunction and the growth of prostatic cancer cells is influenced by oestrogens and androgens. The incidence of prostatic cancer is low in communities with highlegume intake and, conversely, is high in Western societies. Phyto-oestrogens are though to protect from development of prostatic cancer. One mechanism may be the effect of phyto-oestrogens on lowering the proportion of unbound:bound reproductivehormones in the blood. However, there is other evidence to suggest that phyti-oestrogens, particularly isoflavones, can have a direct influence on certain cellular enzymes within prostatic cells.
Pre-menstrual syndrome has uncertain aetiology and pathogenesis, although most certainly is associated with reproductive hormone dysfunction. It also is a syndrome which has reportedly lower incidence in communities maintaining traditionalhigh-legume diets. It is proposed that phyto-ostroegens will alleviate this condition by restoring balance to oestrogen metabolism.
Menopausal syndrome is associated with changes in the oestrogen profile in the body with advancing age. Adverse clinical symptoms may be treated with oestrogen replacement therapy. There is evidence that foodstuffs high in phyto-oestrogens area suitable alternative to synthetic hormones in this respect, producing alleviation of adverse clinical symptoms. Again, it is proposed that phyto-oestrogens will function by restoring balance to oestrogen metabolism.
Benign (or cystic) breast disease has unknown aetiology. However, its association in women with certain stages of the menstrual cycle is strongly suggestive of oestrogen dysfunction. There currently is no successful treatment of this condition. Phyto-oestrogens are proposed to successfully treat this condition by restoring balance to oestrogen metabolism. Atherosclerosis is associated with cholesterol metabolism which in turn is associated closely with oestrogen metabolism. The generallyhigher incidence of atherosclerosis in young men versus young women, the rising incidence in women following menopause, and the lower incidence in post-menopausal women receiving oestrogen replacement therapy, all point to the moderating influence ofoestrogens on cholesterol metabolism. A prime effect of oestrogens on cholesterol metabolism is stimulation of the liver to process cholesterol, particularly the highly atherogenic low-density lipoproteins and very low-density lipoproteins, into bilesalts. It is proposed that phyto-oestrogens have an important hypocholesterolaemic effect in humans. There may be a variety of mechanisms involved, but one may be the stimulation by phyto-oestrogens of cholesterol catabolism by the liver.
MODES FOR CARRYING OUT THE INVENTION
The invention is now described with reference to various examples.
EXAMPLE 1
Preparation of Red Clover Product
Tablets were prepared using red clover in accordance with the following procedure. The raw plant material is harvested and dried; such drying being either sun-drying or from applied heat. The dried product is then preferably chaffed, before thefollowing extraction step, although this can be omitted if desired.
The dried material is extracted in an aqueous:organic solvent mix. The aqueous phase is required to extract the water-soluble glycoside form of isoflavones, while the organic solvent is required to solubilise the water-insoluble algycone form. The organic solvent can be either alcohol, chloroform, acetone or ethyl acetate. The ratio of solvent in the water can be between 0.1% and 99.9%. The preferred method is to use 60% alcohol in water.
The isoflavones are extracted by exposing the plant material to the water:solvent mix. The exposure time in general terms is indirectly proportional to the temperature of the mixture. The temperature of the mix can range between ambienttemperature and boiling temperature. The exposure time can be between 1 hour and 4 weeks or even longer. It has been determined that the adequate items for maximal recovery of isoflavones are 2 weeks at 50.degree. C. and 24 hours at 90.degree. C. Thesupernatant is separated from the undissolved plant material and the organic solvent removed by distillation. The aqueous supernatant then is concentrated, typically by distillation.
Additional processing steps can be used, if desired, to convert the extracted natural product to capsule, tablet, or other convenient form for ingestion, using normal techniques for doing this. Otherwise the product can be packaged as aconvenient food additive.
EXAMPLE 2
Preparation of Soya Hypocotyl Product
Soyabeans were heated in dry air so that the hull became brittle. The beans then were processed through a tumble mill which removed the hull and split the bean the two cotyledons and the small-sized hypocotyl which separated from each other. The light-weight hulls then were removed by an air stream. The small-sized hypocotyls were separated from with larger cotyledons by sieving through a steel wire mesh with apertures of 1 mm.times.1 mm. This yields approximately 87% purity of hypocotylswith 13% contamination of small cotyledon chips.
Normal soybean processing steps isolate the hulls and then these are discarded or processed separately for use in human and animal foodstuffs. The hypocotyls normally are not separated and are processed along with the cotyledons. However, asmall number of soybean processors are separating hypocotyls by the above methods in order to reduce the astringent taste of soyflour for human consumption, and currently these hypocotyls are either discarded or processed to flour for use in animal feed.
EXAMPLE 3
Effect of Administering Red Clover Extract to Humans
Seven normal individuals were studied for the comparative effects of red clover extract and whole legumes on blood cholesterol levels. All the individuals were consuming a standard Western diet with minimal levels of legumes.
Three men consumed between 100-150 g haricot or navy beans daily for 3 weeks as a supplement to their normal diet. This yielded an approximate daily isoflavone dosage or between 60-100 mg.
Four other individuals (3 men, 1 women) consumed 5 g of red clover extract containing 100 mg isoflavones daily for 3 weeks.
Total serum cholesterol levels were determined immediately before and immediately following the challenge.
TABLE-US-00003 Pre-treatment Post-treatment % change Beans only Patient 1 5.77 5.46 -5.4 Patient 2 6.24 6.12 -1.9 Patient 3 7.45 8.51 +14.3 Red clover extract Patient 5 6.53 5.90 -9.6 Patient 6 7.43 6.63 -10.08 Patient 7 6.33 5.50 -13.1 Patient8 6.98 7.28 +4.3
The red clover extract had a significantly (P<0.05) greater hypocholesterolaemic effect than did the whole beans.
Neither of the treatments produced any untoward side effects, although the whole bean eaters reported greater difficulty with compliance of treatment than did those taking the red clover extract.
EXAMPLE 4
Effect of Administering Soy Hypocotyls to Humans
Fifteen volunteers (8 women, 7 men) were given 5 g of soy hypocotyl containing (45 mg daidzein and 5 mg genistein) daily for 2 months. The hypocotyl was consumed as a powder added to the diet.
The effects on cholesterol levels are shown in the following table. The individuals are grouped according to their pre-treatment cholesterol levels (high, medium, low).
TABLE-US-00004 Range (mean) unmol/L n Pre-treatment Post-treatment Group 1 6 6.3-8.4 (7.1) 5.4-6.5 (6.1) Group 2 6 5.0-6.2 (5.5) 4.7-5.9 (5.1) Group 3 3 3.3-4.7 (4.2) 3.4-4.6 (4.1)
The results show a significant fall in total cholesterol levels in those individuals with cholesterol levels considered to be at the upper end of the normal range.
In addition, 1 women reported substantial amelioration of her benign breast disease problem associated with mid-cycle swelling and tenderness, and another women reported regularisation of her menstrual cycle and reduced menstrual bleeding. Bothof these effects were regarded as beneficial.
No other side-effects were reported as a result of the treatment.
* * * * * |
|
|
|
